Baidu
map

J Exp Med:新研究发现影响哮喘的关键蛋白质

2018-10-22 张家伟 新华网

英国弗朗西斯·克里克研究所日前发布的一项新研究发现,有一种蛋白质对于调控过敏性气道炎症起到关键作用,相关机制有助于未来找到更好的哮喘疗法。


英国弗朗西斯·克里克研究所日前发布的一项新研究发现,有一种蛋白质对于调控过敏性气道炎症起到关键作用,相关机制有助于未来找到更好的哮喘疗法。

哮喘是一种常见的慢性气道炎症,常导致反复发作的喘息、气促、胸闷、咳嗽等症状,严重影响患者生活质量。

克里克研究所与帝国理工学院、公司合作,在实验室中利用特殊培养的小鼠来观察一种名为“ABIN-2”的蛋白质如何影响尘螨引起的气道炎症。

研究人员发现,小鼠肺部的树突细胞能捕获气道中的过敏原并激活免疫系统。如果阻止“ABIN-2”蛋白质发挥关键的信号作用,树突细胞就会分泌出更多名为“CCL24”的微小信号蛋白质。这种蛋白质会使气道中的炎症加剧并产生黏液,最终导致小鼠患上严重的过敏性气道炎症。

报告作者之一、基因泰克公司的威尔逊博士说,这项研究显示或许能通过调控“ABIN-2”蛋白质在树突细胞中的信号作用,来避免严重的气道炎症以及哮喘等。

相关研究已刊登在新一期美国《实验医学杂志》上。

原始出处:

Sonia Ventura,et al.ABIN-2 inhibition of HDM allergic airway inflammation.Journal of Experimental Medicine| October 18, 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753435, encodeId=1a661e53435b5, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 02 15:53:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027618, encodeId=5f0f202e618d0, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Jan 08 15:53:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765743, encodeId=2ec31e65743f3, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 01 08:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297057, encodeId=a9df129e057d5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609204, encodeId=6473160920459, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753435, encodeId=1a661e53435b5, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 02 15:53:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027618, encodeId=5f0f202e618d0, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Jan 08 15:53:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765743, encodeId=2ec31e65743f3, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 01 08:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297057, encodeId=a9df129e057d5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609204, encodeId=6473160920459, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753435, encodeId=1a661e53435b5, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 02 15:53:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027618, encodeId=5f0f202e618d0, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Jan 08 15:53:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765743, encodeId=2ec31e65743f3, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 01 08:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297057, encodeId=a9df129e057d5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609204, encodeId=6473160920459, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1753435, encodeId=1a661e53435b5, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 02 15:53:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027618, encodeId=5f0f202e618d0, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Jan 08 15:53:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765743, encodeId=2ec31e65743f3, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 01 08:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297057, encodeId=a9df129e057d5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609204, encodeId=6473160920459, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1753435, encodeId=1a661e53435b5, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 02 15:53:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027618, encodeId=5f0f202e618d0, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Jan 08 15:53:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765743, encodeId=2ec31e65743f3, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Aug 01 08:53:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297057, encodeId=a9df129e057d5, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609204, encodeId=6473160920459, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 24 07:53:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]

相关资讯

Eur Respir J:早期哮喘发病能增加儿童肥胖风险么?

过去几十年当中,儿童哮喘和肥胖的并行发生促使了人们去探究肥胖是哮喘风险因子的研究。然而,哮喘在肥胖发生当中的作用却很少了解。最近,有研究人员调查了是否早期的哮喘发病和相关的症状与儿童时期发张为肥胖的风险相关。研究包括了21130名儿童,他们出生于1990年到2008年之间。研究人员对非肥胖儿童3-4岁时开始进行跟踪调查肥胖的发生情况,直到8岁。研究人员还对3-4岁的儿童进行了医生诊断哮喘、喘息和过

八成哮喘患者都有这个病 而这个病几乎谁都逃不过

进入秋季,一早一晚天气开始变凉,此时正处于季节交替的时候。今天上午定焦大叔来到首都儿科研究所的哮喘科,医院楼道里站满了等待就诊的孩子和家长。11诊室,正在出诊的是哮喘科刘传合医生。刘医生正在给一位小女孩听诊,电脑前另一位年轻医生飞快地记录着孩子的病例。

Environ Int:在上海,尿邻苯二甲酸酯代谢物与儿童哮喘和过敏症状相关

在中国,很少有关于尿邻苯二甲酸酯与儿童哮喘和过敏性症状相关性的研究,然而,研究人员却观察到了儿童哮喘和过敏性疾病流行度的持续性增加。最近,有研究人员评估了上海儿童对邻苯二甲酸盐的接触水平以及其余哮喘和过敏性鼻炎之间的关系。上海也是儿童哮喘流行率最高的中国城市。研究人员在所有参与者中检测到了10种邻苯二甲酸酯代谢物中的9种(平均检出率为93.2%)。通过多变量逻辑回归分析,研究人员发现在邻苯二甲酸单

Clin Exp Allergy:6岁时候的非特应性鼻炎与随后哮喘的发展相关

之前,有研究人员假设过敏性鼻炎与哮喘的相关性可以归结到儿童时期呼吸道炎症的持续临床表现。早期非过敏性鼻炎与哮喘的关系仍旧没有很好的研究。最近,有研究人员进行了旨在确定是否早期的鼻炎与成年时候的哮喘的风险相关,以及是否该相关性与过敏无关。研究总共有521名参与者符合入选要求。与非特应性非鼻炎组相比,在调整了性别、种族、母亲肖传、母亲教育和抽烟以及6岁时不少于4次感冒历史后,非特应性鼻炎患者在8岁到3

BMC Pulm Med:过去20年哮喘、鼻炎和呼吸系统症状流行度变化

最近,有研究人员调查了过去20年成年人中呼吸道症状和障碍以及与之相关的出生时间、生活方式和睡眠相关变量的变化情况。研究包括了6085名女性和5184名男性,年龄在20-44岁之间,他们随机选自北欧7个中心,并且跟踪调查了20年。参与第一次调查的参与者数量达到了21595名,并且11269名参与了所有的3项调查。参与者被分成了3个出生年龄段:1944-1955, 1956-1965和1966-197

Ann Agric Environ Med:哮喘、鼻炎和湿疹与对乙酰氨基酚使用的相关性分析

对乙酰氨基酚是一种常见的儿童使用药物,越来越多的流行病学研究表明对乙酰氨基酚的使用可能是哮喘、过敏性鼻炎和特应性湿疹的风险因子。最近,有研究人员确定和鉴定了对乙酰氨基酚的使用与哮喘、过敏性鼻炎和特应性湿疹症状之间的相关性。研究包括了6-7岁的儿童(n=4510)、13-14岁的青少年(n=4721)和20-44岁的成年人(n=9386),分别占比 24.2%, 25.4%和50.4%。研究发现,乙

Baidu
map
Baidu
map
Baidu
map